Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.44 |
| ▸ | CDK9 | P50750 | 4/20 | 0.44 |
| ▸ | EIF2AK2 | P19525 | 4/20 | 0.44 |
| ▸ | CDK1 | P06493 | 4/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.37 |
| ▸ | CDC7 | O00311 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | PRKACA | P17612 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398202 | 0.81 | MKNK1 (0.53) | CDK2EIF2AK2CDK4MKNK2GSK3B | |
| SCHEMBL7855837 | 0.77 | CYP2D6 (0.36) | CDK2CCNA2CDK1CCNB1CDK4 | |
| SCHEMBL5100516 | 0.77 | VCP (0.47) | CDK2CCNA2CCNT1CDK9CYP1A2 | |
| SCHEMBL5095181 | 0.74 | MKNK1 (0.42) | CDK2CCNA2CCNT1CDK9EIF2AK2 | |
| SCHEMBL5093415 | 0.74 | PIK3CA (0.55) | CDK2CCNA2CCNT1CDK9CDK1 | |
| SCHEMBL19322388 | 0.72 | ALDH1A1 (0.67) | CYP1A2CYP2C19CXCR4ALDH1A1FABP1 | |
| SCHEMBL5100245 | 0.72 | ABL1 (0.58) | PRKACA | |
| SCHEMBL5099513 | 0.71 | NISCH (0.42) | CDK2CCNA2CCNT1CDK9EIF2AK2 | |
| SCHEMBL5100580 | 0.70 | MEN1 (0.47) | CYP1A2CYP2C19ROCK2 | |
| SCHEMBL5092325 | 0.70 | CSNK2A1 (0.45) | CDK2CCNA2CCNT1CDK9CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| EP-1087963-B1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-6417185-B1 | HETEROCYCLIC ENZYME INHIBITORS | CHIRON CORPORATION | 2002-07-09 | — | — | US | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CDK2 133/4885CCNA2 2364/4885CCNT1 1552/4885 |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CDK2 176/4885CCNA2 2505/4885CCNT1 1675/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CDK2 176/4885CCNA2 2505/4885CCNT1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.